Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$146.67 USD
+1.39 (0.96%)
Updated May 31, 2024 03:59 PM ET
After-Market: $146.60 -0.07 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Johnson & Johnson [JNJ]
Reports for Purchase
Showing records 381 - 400 ( 499 total )
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Industry Report ; MED PRODUCTS; This report contains brief updates on the following: MDT, JNJ. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: ZACKS INVESTMENT RESEARCH
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
4Q Preview: Positive Pre-Announcements Bode Well for 2015
Provider: WEDBUSH SECURITIES INC.
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
CTAD?14: A Renewed Focus Toward the Development of Symptomatic Agents, and our Award for Preclinical ''''One to Watch''''
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Recent Drug Launch Weekly Retail Sales Tracker - Week Ended Oct 3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
3Q Preview: Stable-to-Improving Procedure Trends
Provider: WEDBUSH SECURITIES INC.
Company: Johnson & Johnson
Industry: Large Cap Pharmaceuticals
Recent Drug Launch Weekly Retail Sales Tracker - Week Ended August 22
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D